A New Clinical Trial Explores MDMA-Assisted Therapy for Social Anxiety Disorder
Social Anxiety Disorder (SAD) is one of the most common and impairing mental health conditions. About 13 percent of people in the United States will experience it at some point in their lives. For many, it begins in adolescence and follows a chronic course. While cognitive behavioral therapy and medications such as SSRIs can help, a large percentage of people remain symptomatic, drop out of treatment, or never access care at all.
A newly published clinical trial protocol outlines an innovative approach: MDMA-assisted therapy (MDMA-AT) for social anxiety disorder. The study was developed by Kati Lear, PhD, Brian Pilecki, PhD, and Jason Luoma, PhD from Portland Psychotherapy, along with collaborators, and represents the first pilot trial of MDMA-AT for SAD outside the context of autism.
Why Consider MDMA-Assisted Therapy for Social Anxiety?
MDMA is a compound that affects serotonin, dopamine, norepinephrine, and hormones such as oxytocin. In therapeutic settings, it has been shown to increase feelings of safety, trust, and connection while reducing defensiveness and fear. These effects are part of why MDMA-assisted therapy has shown strong results in clinical trials for PTSD.
Social anxiety disorder is characterized by intense fear of negative evaluation and deep concerns about being judged, rejected, or exposed as flawed. Many people with SAD struggle with chronic shame, self-criticism, social avoidance, and a heightened perception of social threat.
The research team proposes that MDMA-AT may directly target these maintaining processes. Rather than focusing only on symptom reduction, this study examines how MDMA-AT might change core psychological mechanisms such as shame, belongingness, self-concealment, and self-compassion.
Study Design: A Careful, Structured Approach
This study is a randomized, delayed-treatment pilot trial with 20 participants who meet criteria for generalized social anxiety disorder.
Participants are randomly assigned to either:
Immediate MDMA-assisted therapy
A delayed treatment group that begins the same intervention after 16 weeks
The active treatment includes:
Three preparation sessions
Two MDMA medicine sessions
Six integration sessions
Medicine sessions last about eight hours and are conducted by a two-therapist team. Participants receive an initial dose of MDMA, followed by a supplemental dose unless contraindicated. Integration sessions help people process their experience and apply insights to daily life.
The primary outcome measure is the Liebowitz Social Anxiety Scale, administered by independent raters who are blinded to study condition. Secondary outcomes assess functional impairment, shame, belonging, self-compassion, and related processes.
Importantly, safety is central. The protocol includes extensive medical screening, ongoing monitoring of vital signs, suicidality assessments, and involvement of a designated support person after medicine sessions.
A Focus on Processes of Change
One of the most distinctive aspects of this trial is its emphasis on understanding how MDMA-AT works.
The authors outline several hypothesized mechanisms:
1. Memory reconsolidation of shame-based experiences
Many people with SAD carry painful memories of rejection or humiliation. MDMA may create a context of safety that allows these memories to be revisited and updated, reducing their emotional intensity.
2. Strengthened therapeutic alliance
MDMA appears to increase feelings of trust and connection, which may deepen the therapeutic relationship. For people who fear social judgment, this experience alone may be corrective.
3. Reduced social threat sensitivity
People with SAD often show heightened reactivity to perceived social threat. MDMA has been shown to reduce amygdala activation in response to threatening social cues, potentially shifting how people interpret social situations.
4. Increased self-compassion and reduced self-criticism
Experimental studies suggest MDMA can increase feelings of self-compassion. Since harsh self-criticism plays a central role in social anxiety, reducing it may open space for more flexible and authentic social behavior.
The study also includes behavioral tasks and physiological measures such as heart rate variability to explore changes in social safety and engagement over time.
Why This Matters
Current treatments for social anxiety are helpful for many people, but remission rates are far from perfect. Meta-analyses suggest that a substantial portion of people who complete cognitive behavioral therapy still meet criteria for the disorder. Dropout rates are also meaningful, especially in exposure-based treatments.
MDMA-assisted therapy offers a different model. Instead of repeated exposure sessions or daily medication use, MDMA-AT involves a small number of carefully structured medicine sessions embedded within psychotherapy. Early research in other conditions suggests effects may endure for months after treatment.
This pilot trial is designed to estimate effect size, evaluate feasibility and safety, and inform future large-scale randomized controlled trials.
What Comes Next for the Trial
MDMA-assisted therapy for social anxiety disorder remains investigational. This study does not yet provide outcome data, but it lays the groundwork for testing whether this approach can offer meaningful relief for people who continue to struggle despite existing treatments.
By examining both symptom reduction and underlying processes of change, this research moves the field toward a more nuanced understanding of how psychedelic-assisted therapies may work.
As the study progresses, its findings may help clarify whether MDMA-AT can become a viable, evidence-based option for people living with social anxiety disorder.
You can read the full study protocol here.
Interested in participating? Portland Psychotherapy is currently enrolling participants for clinical research on MDMA-assisted therapy. Visit our research page to learn about eligibility and current trials.
This article is for educational purposes and does not constitute medical advice. MDMA-assisted therapy is currently investigational and available only through approved clinical trials.